bioecon Member area
Technology · Health & biomedicine / Diagnostics & medtech

Diagnostics & biosensors

Advanced analytical devices detecting biological markers to enable rapid, precise disease identification and monitoring.

Risk: low Diagnostics US · EU · CN · IN Science: why it works → verified 2026-07-28 · 11 Sources (0 independent)

1 · What it gives

Diagnostics and biosensors represent the critical first step in modern clinical pathways, converting biological signals into actionable medical data. By combining biorecognition elements (antibodies, nucleic acids, enzymes) with physicochemical transducers, these devices quantify biomarkers with extreme sensitivity. The global market, serving billions of patients, is rapidly shifting from centralized lab testing to rapid Point-of-Care (POC) molecular and genomic diagnostics, fundamentally accelerating treatment timelines and outbreak responses.

The key directions of diagnostics and biosensors are:

  1. In-Vitro Diagnostics (In-Vitro Diagnostics): traditional lab-based biochemical testing of blood and tissue representing over 70% of total diagnostic volume.
  2. Molecular Diagnostics (Molecular Diagnostics): analyzing DNA and RNA via PCR or sequencing to identify infectious agents and genetic mutations with 99% accuracy.
  3. Point-of-Care Testing (Point-of-Care Testing): decentralized rapid testing delivering clinical-grade results in under 30 minutes at the patient’s bedside.
  4. Continuous Biosensors (Continuous Biosensors): wearable patches monitoring chronic disease markers, such as continuous glucose monitors (CGMs) for millions of diabetics.

Sectoral value chain#

[Biomarker R&D] ──> [Assay Dev] ──> [Manufacturing] ──> [Clinical Dist]
                                  │
                          (Patient Data)
                                  │
                                  ▼
[Therapeutics] <─── [Clinical Dec] <─────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
1. Biomarker discoveryIdentifying molecular signatures of diseaseIn: Clinical data.
Out: Target biomarkers.
2. Assay developmentDesigning the chemical or genetic detection mechanismIn: Target biomarkers.
Out: Diagnostic assays.
3. Hardware engineeringBuilding readers, microfluidic cartridges, and sensorsIn: Assays, materials.
Out: Diagnostic devices.
4. ManufacturingMass-producing test kits and reagents under GMPIn: Diagnostic devices.
Out: Commercial kits.
5. Clinical deploymentDistributing to central labs and POC facilitiesIn: Commercial kits.
Out: Patient testing.
6. Data integrationLinking test results to electronic health recordsIn: Patient testing.
Out: Treatment decisions.

Cross-cutting technologies of the sector:

  • Microfluidics (Lab-on-a-Chip): miniaturizing complex laboratory liquid handling into disposable plastic cartridges.
  • CRISPR Diagnostics: utilizing Cas nucleases (like Cas12/Cas13) for ultra-rapid, highly specific nucleic acid detection without complex thermal cycling.
  • Next-Generation Sequencing (NGS): high-throughput DNA sequencing enabling comprehensive oncology panels and non-invasive prenatal testing (NIPT).

2 · What it replaces 2 · matched by industry

D2E4Crop disease forecasting models, spore traps, pheromone and smart pest traps and field diagnostics — spray when risk is real instead of calendar-based fungicide and insecticide programmes
Replaces: Fixed-interval ("calendar") protective fungicide sprays and routine insecticide applications regardless of pest pressure
EAC
D2E–On-farm culture, PCR panels, rapid tests and veterinary laboratory services for livestock and aquaculture — treat what is diagnosed instead of blanket and prophylactic antibiotic treatment
Replaces: Blanket treatment of every clinical mastitis case, group metaphylaxis on suspicion, prophylactic antibiotics in hatcheries and ponds, …
DIAG

3 · How to implement 6 steps

  1. 1
    Biomarker validationTesting & analytics
    Identifying and validating specific nucleic acid sequences or antigens that definitively indicate the presence of a pathogen or disease state.
    Who can do this step matched automatically
    GenScript ProBio / Genscript China
    ✓ GMP industrial scale
    “ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”
    BRAIN Biotech Germany
    industrial scale
    “As a contract research organization (CRO), we provide smart, rapid, and effective solutions using cutting-edge technologies to drive customer success.”
    Vaxxinova Norway Norway
    industrial scale
    “Vaxxinova develops, produces and markets a wide range of innovative vaccines and diagnostic services to protect livestock and fish against diseases.”
  2. 2
    Assay formulationFormulation & blendingTesting & analytics
    Designing specific primers, probes, and enzymes, and freeze-drying them into stable reagent beads that can survive room-temperature shipping.
    Who can do this step matched automatically
    Advanced Enzyme Technologies (NSE) India
    ✓ GMP 500 m3
    “This is a satellite blending, mixing and formulation facility, located at Vashind near Shahapur and dedicated to the company’s Animal Nutrition business.”
    SyAqua Group Thailand
    “vannamei genetics (broodstock, nauplii, and post-larvae) built on genomic selection/marker-assisted selection plus quantitative genetics (BLUP), with disease resistance screening …”
    India Glycols (NSE) India
    ✓ GMP 7,500 MT/ industrial scale
    “Recent expansions and new facilities across процесses: MEG production growth (up to 200,000 MTPA), EO purification, ethoxylate, sulphation, formulation plants, and …”
  3. 3
    Microfluidic molding
    Using precision injection molding to create intricate plastic cartridges containing microscopic channels and reaction chambers.
  4. 4
    Cartridge assembly
    Loading the lyophilized reagent beads into the microfluidic cartridges and hermetically sealing them under strict ISO 13485 cleanroom conditions.
  5. 5
    QC & calibrationTesting & analytics
    Running statistical batches of cartridges against known positive and negative clinical controls to guarantee 99%+ sensitivity and specificity.
    Who can do this step matched automatically
    GenScript ProBio / Genscript China
    ✓ GMP industrial scale
    “ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”
    BRAIN Biotech Germany
    industrial scale
    “As a contract research organization (CRO), we provide smart, rapid, and effective solutions using cutting-edge technologies to drive customer success.”
    Vaxxinova Norway Norway
    industrial scale
    “Vaxxinova develops, produces and markets a wide range of innovative vaccines and diagnostic services to protect livestock and fish against diseases.”
  6. 6
    Clinical deployment
    Shipping the finished cartridges to decentralized clinics and emergency rooms, where patient samples are loaded directly for automated 30-minute processing.

4 · Who delivers

Matched suppliers (matched automatically)

Vaxxinova NorwayNorwayNot classifiedactive
SartoriusGermanyProduceractive
HipraSpainProduceractive
CodexisUnited StatesProduceractive

In the services and supply catalogue 3 · paid service

Analytical & testing services · Laboratory & analytical instruments · Reagents & kits

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Roche🇨🇭 SwitzerlandCobas systemsHigh-throughput IVDcommercial
Abbott🇺🇸 USABinaxNOW & FreeStyleRapid POCT and CGMscommercial
Danaher (Cepheid)🇺🇸 USAGeneXpertCartridge-based PCRcommercial
bioMérieux🇫🇷 FranceBioFire systemsSyndromic PCR testingcommercial
BGI Group🇨🇳 ChinaDNBSEQ platformsHigh-throughput genomicscommercial
Molbio Diagnostics🇮🇳 IndiaTruenatBattery-operated real-time PCRcommercial
Wondfo Biotech🇨🇳 ChinaRapid lateral-flow POCTpregnancy/COVID rapid testscommercial
Mylab Discovery Solutions🇮🇳 IndiaMolecular diagnosticsindigenous PCR/POCT platformscommercial
Hologic🇺🇸 USAMolecular & women’s-health IVDPanther molecular platformcommercial
DiaSorin🇮🇹 ItalyImmunodiagnostics & molecularLIAISON chemiluminescencecommercial
Getein Biotech🇨🇳 ChinaRapid POCT immunoassaycardiac-marker rapid panelscommercial

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

The US dictates the global diagnostics market through dominant legacy manufacturers and a massive venture-backed ecosystem pushing POC innovations.

molecular leadership, CGM dominance, FDA pathways#

  • Abbott Diagnostics: dominating the massive POC and continuous glucose monitoring (CGM) consumer markets.
  • Danaher (Cepheid): leading the rapid molecular diagnostics space with its ubiquitous GeneXpert automated PCR platform.
  • Hologic: leading molecular diagnostics for women’s health (HPV, STI) on its high-throughput Panther platform, plus digital breast tomosynthesis.
  • FDA 510(k) & EUA: setting stringent premarket notification standards while utilizing Emergency Use Authorizations to rapidly combat pandemics.
European Union

The EU is a stronghold of traditional microbiology and in-vitro diagnostics, currently navigating a major, disruptive regulatory overhaul.

microbiology leadership, IVDR transition, precision medicine#

  • Roche Diagnostics: commanding a massive share of the global centralized clinical chemistry and immunodiagnostics market.
  • bioMérieux Expertise: leading the world in clinical microbiology and rapid syndromic testing for infectious diseases.
  • DiaSorin: Italian specialist in immunodiagnostics and molecular testing, running its LIAISON chemiluminescence platform across centralized labs.
  • IVDR Implementation: transitioning to the stringent In Vitro Diagnostic Medical Devices Regulation (IVDR), which requires extensive clinical evidence for legacy tests.
China

China is aggressively localizing its diagnostic supply chains, moving from basic lateral flow assays to high-end genomics and molecular platforms.

genomic sequencing, domestic substitution, mass screening#

  • BGI Group Genomics: driving down the global cost of sequencing and executing massive state-sponsored population health screenings.
  • Wondfo Biotech: scaling highly affordable POCT solutions for both domestic rural healthcare and massive export markets.
  • Getein Biotech: Nanjing-based rapid POCT immunoassay maker (cardiac and inflammatory markers) scaling affordable point-of-care panels.
  • Volume-Based Procurement (VBP): government-led centralized purchasing driving intense price competition and forcing out foreign legacy IVD systems.

6 · Money: tenders & grants

TenderGreece – Biochemical analysers – ΗΛΕΚΤΡΟΝΙΚΟΣ ΑΝΟΙΚΤΟΣ ΔΙΑΓΩΝΙΣΜΟΣ ΑΝΩ ΤΩΝ ΟΡΙΩΝ ΣΕ ΕΥΡΩ ΓΙΑ ΤΗΝ ΠΡΟΜΗΘΕΙΑ …
ΓΕΝΙΚΟ ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΟΓΚΟΛΟΓΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ "Ο ΑΓΙΟΣ ΣΑΒΒΑΣ" · Greece
Dec 11, 2026
56 days
TenderNetherlands – Blood-testing reagents – Gevalideerde Totaaloplossing voor de hielprikscreening op …
Rijksinstituut voor Volksgezondheid en Milieu (RIVM) · Netherlands
Nov 10, 2026
25 days
GrantCircular innovative advanced materials: facilitating the transition from design to markets (RIA) (Innovative …
European Commission · EU
Feb 2, 2027
109 days
GrantImproving analytical capacity for sustainable competitiveness of the agricultural sector
European Commission · EU
May 11, 2027
207 days
GrantTextile circularity through advanced processing and manufacturing technologies and system approaches (IA) …
European Commission · EU
Feb 2, 2027
109 days

7 · Tech stack & innovations

The modern diagnostics stack merges advanced biochemistry with precision micro-engineering and optics.

  1. Multiplex Molecular Platforms:
    • Amplifies and detects dozens of distinct genetic targets (syndromic panels) simultaneously from a single patient swab.
    • Utilizes lyophilized (freeze-dried) reagents inside sealed cartridges to eliminate cold-chain logistics entirely.
  2. Electrochemical Biosensors:
    • Employs immobilized enzymes (like glucose oxidase) on micro-electrodes to convert biological binding events directly into measurable electrical currents.
    • Minimizes form factors, enabling minimally invasive, 14-day wearable sensors that broadcast continuously to smartphones.
  3. Digital Pathology & AI:
    • Scans traditional tissue biopsies into gigapixel digital slides.
    • Deploys deep learning algorithms to highlight malignant cells, reducing pathologist workload by 30% and eliminating human error.

Sources 11 · 0 independent · 11 producer sites

Producers' own sites 11

  1. Roche producer checked 2026-05-21 · link not kept
  2. Abbott producer checked 2026-05-27 · link not kept
  3. Danaher producer checked 2026-06-12 · link not kept
  4. Biomerieux producer checked 2026-06-05 · link not kept
  5. Bgi group producer checked 2026-06-24 · link not kept
  6. Wondfo biotech producer checked 2026-06-24 · link not kept
  7. Molbio diagnostics producer checked 2025-09-15 · link not kept
  8. Mylab discovery solutions producer checked 2026-06-11 · link not kept
  9. Hologic producer checked 2026-07-24 · link not kept
  10. Diasorin producer checked 2026-05-22 · link not kept
  11. Getein biotech producer checked 2026-07-28 · link not kept